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INTRODUCTION
Dosing recommendations contained in product labeling 
may differ from dosing implemented in clinical practice be-
cause the recommendations reflect the design and results of 
registration studies. These studies may be designed without 
the benefit of complete knowledge of dose-response relation-
ships, and implemented in study subjects who may differ from 
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the patients who will actually receive these medications.
1 After 
gaining clinical experience with new medications, clinicians 
may modify their prescribing practices, with some anti-psy-
chotics being prescribed at much lower or much higher doses 
than originally anticipated, such as has been reported for rispe-
ridone, olanzapine, and quetiapine in hospitalized patients.
2 
Ziprasidone is a novel anti-psychotic with a unique pattern 
of receptor affinity that distinguishes it from other anti-psy-
chotics. Ziprasidone is a potent antagonist at the serotonin 
5-HT2A, 5-HT1D, 5-HT2C receptors, and dopamine D2 re-
ceptor with a high 5-HT2A/D2 ratio, and a potent agonist at 
5-HT1A receptors.
3 In randomized, placebo-controlled studi-
es involving patients with acute bipolar manic or mixed epi-
sodes, ziprasidone monotherapy was shown to produce rapid, 
sustained improvements in manic and psychotic symptoms 
relative to the baseline and placebo at study end points, and 
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demonstrated a favorable safety and tolerability profile.
4,5 
The ziprasidone product label6 recommends an initial daily 
dose of 80 mg/d, with an increase to 120 or 160 mg/d on the 
2nd day of treatment for patients with bipolar mania. A recent 
analysis of data from a wide range of fixed- and flexible-dose 
trials showed that doses of ziprasidone between 120 and 160 
mg/day were associated with superior and more rapid impro-
vement in overall psychopathology than lower doses of this 
medication.
7,8 These study results also revealed that ziprasi-
done doses >120 mg were associated with lower rates of early 
discontinuation due to inadequate clinical responses within 
14 days of treatment, as compared to lower doses. Furthermore, 
in placebo-controlled trials, ziprasidone (120-160 mg/day) 
was associated with a low rate of discontinuation due to ad-
verse events.
9,10
Although the optimal dose of ziprasidone in controlled cli-
nical trial settings for schizophrenia has been well-document-
ed, there is little evidence in support of the proper dose of zipra-
sidone in patients with bipolar disorder, especially when com-
bined with a mood stabilizer. Moreover, East Asian patients 
receive relatively lower doses of anti-psychotics than their Cau-
casian counterparts.
11-13
Such findings suggest the need for further evaluation of the 
relationship between ziprasidone dosing and effectiveness in 
an Asian ‘real world’ clinical practice. 
The objective of this study was to determine the relationship 
between initial ziprasidone dose and efficacy, and the safety of 
a ziprasidone and divalproex combination in the treatment of 
patients with bipolar manic or mixed episodes. 
METHODS
Participants
The present study was an open-label, multi-center, 6-week, 
flexible-dose study involving combination ziprasidone and di-
valproex for the acute treatment of patients with bipolar ma-
nic or mixed episodes. Patients who fulfilled the inclusion and 
exclusion criteria listed below were eligible for participation 
in this trial. Patients had to be at least 18 years of age at the time 
they enrolled in the study. 
The inclusion criteria included a current DSM-IV
14 diagno-
sis of bipolar disorder with a current manic or mixed episode 
and a requirement for anti-psychotic treatment on the basis of 
clinical experience or investigator preference. At the time of 
entry into the study, the patients had to have a score >20 on the 
Young Mania Rating Scale (YMRS).
15 The exclusion criteria 
were as follows: confirmed organic brain disease, including a 
history of cerebrovascular accidents, brain tumors, or mental 
retardation; co-existing severe medical conditions; a history 
of substance abuse or dependence within 1 month before study 
entry; the presence of any other axis I DSM-IV diagnoses; the 
use of depot anti-psychotics within one cycle before study 
entry; and women who were pregnant or breastfeeding. 
All patients were recruited during between May 2007 and 
December 2007 from 9 nationwide sites in Korea, including 
university-based hospitals or chronic mental institutions. 
Treatment and study procedures
The study subjects were treated with ziprasidone in combi-
nation with divalproex for up to 6 weeks. A washout period 
of 3 days for patients who had received any disallowed con-
comitant medications, such as anti-psychotics other than zi-
prasidone or mood stabilizers other than divalproex, preced-
ed study entry. 
The study used a flexible dosing schedule for ziprasidone 
and divalproex. Patients received 40-80 mg/day of ziprasidone 
on days 1 and 2. After day 3, the dose could be maintained, 
reduced, or increased up to 160 mg/day, based on the inves-
tigator’s experience and patient response. Divalproex was st-
arted at 500 mg/day and increased to 1,000 mg/day on day 2. 
The divalproex dose could be maintained or changed within 
the usual therapeutic dose range. Investigators were instruct-
ed to adjust the doses of the divalproex to obtain serum con-
centrations in the usual therapeutic range (50-120 μg/mL). An-
ti-psychotics other than ziprasidone, and mood stabilizers 
other than divalproex, were not allowed during the trial. Lo-
razepam for agitation (up to 4 mg/day) and anti-Parkinsonian 
medications were allowed, but preventive use was prohibited. 
This study was performed by investigators who had previ-
ous experience with clinical trials and the management of pa-
tients with bipolar disorder. The investigators were all given 
training for the instruments used to assess the efficacy of the 
trial. Prior to beginning the trial, an introductory workshop on 
the study design and methodology for the study was held in 
each district. 
Outcome assessments
The measures used to assess the efficacy of medication in-
cluded the YMRS, the 17-item Hamilton Rating Scale for De-
pression (HAMD),
16 the Brief Psychiatric Rating Scale (BP-
RS),
17 and the Clinical Global Impression-Severity (CGI-S).
18 
The YMRS, HAMD, BPRS, and CGI-S scores were assessed at 
baseline and at weeks 1, 3, and 6 after treatment commenced. 
The Extrapyramidal Symptom Rating Scale (ESRS)
19 was ad-
ministered at each visit in order to assess tolerability. The vital 
signs and weight were recorded at each visit. All adverse events 
attributable to or suspected to be related to the study drug were 
recorded at baseline and at each visit. The patients were cate-
gorized into two groups by the initial dose of ziprasidone.
20 The 
patients who were started on <80 mg/day were included in YS Woo et al. 
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the low-dose start group, and the patients started on 80 mg/day 
were included in the standard-dose start group. 
 
Statistical analysis
The data included all patients who provided both a baseline 
and at least 1 post-baseline data measurement. All patients 
who received at least one dose of the study medication were 
included in the safety analysis. Comparisons of the baseline 
demographic and illness characteristics between the low-and 
standard-dose start groups were performed using an indepen-
dent t-test for continuous variables and a chi-square test or Fi-
sher’s exact test for categorical variables. The mean doses of 
ziprasidone and divalproex were compared between the low-
and standard-dose start groups using an independent t-test. 
The primary efficacy measure was the mean change in the YM-
RS total score from baseline to end-point. Last-observation-
carried-forward (LOCF) analyses of change from baseline to 
endpoint in YMRS, HAMD, BPRS, and CGI-S scores were 
performed. Paired t-tests and repeated measures analysis of 
covariance (ANCOVA) were used to determine whether there 
were significant changes in each efficacy variable over time. 
ANCOVA was conducted with baseline measures, and con-
comitant medications were entered as covariates. ANCOVA 
models included the effects of treatment, low-dose start/stan-
dard-dose start categorization, and interactions of treatment. 
In addition, a responder and remitter analysis was performed 
on the YMRS scores comparing the rate of response and re-
mission among groups by chi-square analysis. A response was 
categorically defined as a >50% reduction on the YMRS scales. 
Remission was defined as a total YMRS score of <12. We also 
performed logistic regression using these variables as predic-
tors and the response and remission as dependent variables. 
To compare the risk of adverse events between the initial dose 
groups, chi-square tests were performed. All statistical tests 
were two-tailed with a significance level of 0.05. Statistical an-
alysis was carried out using SAS, PC version 6.0.
Ethics
The study was conducted according to the Declaration of 
Helsinki and Good Clinical Practices. Written informed con-
sent was obtained from all subjects after they were given an 
extensive explanation of the nature and procedures of the study, 
and patient anonymity should be preserved. The study proto-
col was approved by the Institutional Review or Ethics Com-
mittees at each study site.
RESULTS
Patients
Sixty-five subjects participated in this study. Forty-three pa-
tients (66.2%) were included in the low-dose start group and 
22 patients (33.8%) were included in the standard-dose start 
group. In low-dose start group, most of patients (36/43, 83.7%) 
started ziprasidone on 40 mg/day. The baseline demographic 
and illness characteristics of the patients in the low-and stan-
dard-dose start groups are summarized in Table 1. The base-
line YMRS score was significantly higher (p=0.033) in the st-
andard-dose start group (35.7±9.6) than the low-dose start gr-
oup (30.8±8.1). The other characteristics were similar be-
tween the low- and standard-dose start groups. Twenty-one 
of the 65 patients (32.3%) did not complete the study. The rea-
sons for non-completion were loss to follow-up (n=10, 15.4%), 
withdrawal of consent (n=5, 7.7%), an adverse event (n=3, 
4.6%), lack of efficacy (n=1, 1.5%), non-compliance (n=1, 1.5%), 
and protocol violation (n=1, 1.5%); 17 patients (81.0%) were 
in low-dose start group and 4 patients (19.0%) were in stan-
dard-dose start group (p=0.082). 
Medications
The mean doses of ziprasidone and divalproex used in the 
current study are presented in Table 2. There was no difference 
between the low- and standard-dose start groups with respect 
to the mean doses of ziprasidone (95.0±29.3 mg/day versus 
104.4±31.9 mg/day, p=0.243) and divalproex (916.1±212.8 
mg/day versus 936.5±336.0 mg/day, p=0.774) during the 
study period. Lorazepam was received by 50.0% of the patients 
in the low-dose start group and 68.2% of the patients in the 
high-dose start group (p=0.164). 
Efficacy
By week 6 of treatment, the standard-dose start group show-
ed significant improvements from baseline with respect to the 
YMRS (-26.5±11.0, p<0.0001), CGI-S (-2.6±1.1, p<0.0001), 
BPRS (-19.2±9.4, p<0.0001), and HAMD total scores (-5.0± 
6.0, p=0.001). The YMRS (-16.8±12.1, p<0.0001), CGI-S 
(-1.7±1.4, p<0.0001), BPRS (-13.8±12.4, p<0.0001), and HA-
MD scores (-2.4±6.9, p=0.039) were also decreased signifi-
cantly in the low-dose start group. There were no significant 
group differences in YMRS (F=2.441, p=0.074), CGI-S (F= 
2.487, p=0.075), BPRS (F=1.447, p=0.240), and HAMD total 
score changes (F=1.520, p=0.220) based on repeated mea-
sure ANCOVA. 
However, as shown Figure 1, the response and remission 
rates were significantly different between the two groups. 
The number of patients with a 50% reduction or more in the 
YMRS total score was 19 (86.4%) at the endpoint in the stan-
dard-dose start group and 23 (53.5%) in the low-dose start 
group (p=0.002). The number of patients entering remission 
(YMRS ≤12) at the endpoint was 17 (77.3%) in the standard-
dose start group and 20 (46.5%) in the low-dose start group 210  Psychiatry Investig 2011;8:207-213
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Table 1. Demographic and clinical characteristics
Characteristics









Male 30 (46.2) 15 (68.2) 15 (34.9)
Female 35 (53.8) 7 (31.8) 28 (65.1)
Age 39.2 (11.2) 40.4 (12.1) 38.7(11.0) 0.613
Onset age 27.0 (8.7)0 26.6 (8.3)0 27.2(9.0)0 0.796
Previous number of admissions 2.9 (3.4)0 2.7 (2.1)0 3.0(4.0)0 0.784
Severity 0.059
Mild 7 (10.8) 0 (0)0.0 7 (16.3)
Moderate 16 (24.6) 4 (18.2) 12 (27.9)
Severe  42 (64.6) 18 (81.8) 24 (55.8)
Psychotic features 0.432
Yes 29 (44.6) 8 (36.4) 21 (48.8)
No 36 (55.4) 14 (63.6) 22 (51.2)
Treatment base 0.164
Inpatient 53 (81.5) 20 (90.9) 33 (76.7)
Outpatient 12 (18.5) 2 (9.1)0 10 (23.3)
Concomitant medication during study period
Benzodiazepine 36 (55.4) 15 (68.2) 21 (48.8) 0.138
Hypnotics 16 (24.6) 8 (36.4) 8 (18.6) 0.116
Anti-Parkinsonian 8 (12.3) 2 (9.1)0 6 (14.0) 0.572
Baseline score
YMRS 32.4 (8.9)0 35.7 (9.6)0 30.8 (8.1)0 0.033*
BPRS 46.0 (10.4) 46.1 (10.3) 45.9 (10.6) 0.927
CGI-S 4.6 (1.0)0 4.7 (0.8)0 4.5 (1.1)0 0.373
HAMD 8.8 (6.4)0 9.8 (6.2)0 8.3 (6.5)0 0.403
*p<0.05. YMRS: Young Mania Rating Scale, BPRS: Brief Psychiatric Rating Scale, CGI-S: Clinical Global Impression-Severity, HAMD: Ham-
ilton Depression Rating Scale-17 
Table 2. Mean dose of treatment medications
Medication Visit
Low-dose start  Standard-dose start 
p-value
Mean±SD (mg/day) Mean±SD (mg/day)
Ziprasidone dose Baseline 41.0±7.6 80.0±0.0 0.000*
Week 1 084.2±26.8 117.1±33.0 0.000*
Week 3 114.2±36.6 112.0±32.7 0.829
Week 6 135.4±52.6 108.9±37.7 0.074
Divalproex dose Baseline 0562.5±176.8 0586.4±238.1 0.655
Week 1 0958.8±205.8 0964.3±289.0 0.935
Week 3 1006.9±261.8 1025.0±354.1 0.838
Week 6 1043.5±339.6 1041.7±371.5 0.987
Divalproex serum level Week 1 075.1±35.4 070.7±18.9 0.595
Week 3 080.4±30.0 079.5±25.0 0.926
Week 6 084.4±24.3 080.0±29.6 0.617
*p<0.05YS Woo et al. 
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(p=0.018). 
Based on logistic regression analyses, being on standard-
dose start more than fourfold increased the odds of YMRS 
response (RR, 4.660; 95% CI, 1.097-19.792; p=0.037) and re-
mission (RR, 4.802; 95% CI, 1.326-17.395; p=0.017) at the 
study endpoint. 
Adverse events and safety
The ziprasidone and divalproex combination was well-tol-
erated throughout the 6-week study period. Three adverse 
events led to withdrawal from the study. The reasons for with-
drawal were nausea, drowsiness, and headache in one patient 
each. No statistically significant changes were recorded on the 
ESRS-behavior rating score, total score for Parkinsonism, to-
tal score for dystonia, total score for dyskinesia, CGI scale for 
Parkinsonism, and CGI scale for dyskinesia at the study end-
point compared to the baseline in both groups. There were 
no cases of newly emergent tardive dyskinesia. All adverse 
events were considered mild (n=19, 57.6%) or moderate 
(n=14, 42.4%). No patient reported serious adverse events.
The adverse events that were reported during the study pe-
riod were not significantly different between the two groups. 
Seven patients (31.8%) reported 11 adverse events in the stan-
dard-dose start group, and 14 patients (32.6%) reported 22 
adverse events in the low-dose start group (χ2=0.004, df=1, 
p=0.952). Both treatments were generally tolerable, as shown 
in Table 3. As to extrapyramidal symptoms (EPS), including 
tremors, rigidity, dystonia, and involuntary muscle contrac-
tions, 8 (18.6%) and 4 patients (18.2%) had EPS in the low- 
and standard-dose start groups, respectively. 
The mean weight decreased from 66.3 kg at baseline to 
65.6 kg at week 6. The change in weight was not statistically 
significant (p=0.823). There was no significant group differ-
ences in body weight (F=0.461, p=0.501). The change in wei-
ght was not correlated with the mean doses for the ziprasidone 
or divalproex. The weight was increased in 27 patients (41.5%), 
decreased in 23 patients (35.4%), and unchanged in 15 pa-
tients (23.1%); no patient had a statistically significant (≥7%) 
change in weight.
DISCUSSION
A recent analysis of data from a wide range of fixed- and 
flexible-dose trials showed that an initial high dose of ziprasi-
done is associated with better treatment results and a lower 


















Low-dose start (n=43)                    Standard-dose srart (n=22)
Figure 1. Responder and remission status at study endpoint. Re-
sponse was defined as a >50% reduction in the Young Mania Rat-
ing Scale (YMRS) score from baseline to endpoint. Remission was 
defined as a YMRS ≤12 at study endpoint. Statistical comparison 
was performed using chi-square statistic.
p=0.002
p=0.018
Table 3. Adverse events in low- and standard-dose start groups 
Adverse event Number of patients [N(%)]
Category Symptoms Low-dose start Standard-dose start Total
Neurologic Parkinsonism 8 (18.6) 4 (18.2) 12 (18.5)
  Akathisia 2 (4.7) 2 (9.1) 04 (6.2)
Psychic Somnolence/Sedation 5 (11.6) 1 (4.5) 06 (9.2)
  Anxiety/Agitation  1 (2.3) 0 (0) 01 (1.5)
Disorientation 1 (2.3) 0 (0) 01 (1.5)
Autonomic Micturition disturbance 2 (4.7) 0 (0) 02 (3.1)
  Reduced salivation 1 (2.3) 0 (0) 01 (1.5)
 Gastrointestinal Nausea/vomiting 1 (2.3) 0 (0) 01 (1.5)
  Diarrhea 1 (2.3) 0 (0) 01 (1.5)
 Others Skin rash 0 (0) 1 (0) 01 (1.5)
  Headache 2 (4.7) 0 (0) 02 (3.1)
  Alopecia 1 (2.3) 0 (0) 01 (1.5)
Extremity weakness 1 (2.3) 0 (0) 01 (1.5)212  Psychiatry Investig 2011;8:207-213
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patients than lower doses.
7,8 Although these data were obtain-
ed from patients with schizophrenia, the patients with bipolar 
disorder may have similar findings. The results of this study 
suggest that in a naturalistic setting, initiating a standard dose 
ziprasidone combined with divalproex was significantly asso-
ciated with higher response and remission rates than was initi-
ation of low dose ziprasidone combined with divalproex. Mo-
reover, there was no significant difference in tolerability be-
tween the low- and standard-dose start groups. Taken together 
with findings from a similar study in schizophrenic patients,
20 
these results support the clinical benefits of starting patients 
at a higher dose of ziprasidone. However, because week 1 zip-
rasidone dose of standard-dose start group and low-dose start 
group were significantly different, there is possibility that the 
rate of dose titration, not only initial dose, can affect the re-
sults which favored standard-dose start. Addington et al. also 
reported that slower titration contributed to a higher dropout 
rate for ziprasidone during the first two weeks in schizophren-
ic patients.
21 
In this study, remission was defined as YMRS≤12.
22 Howev-
er, a cutoff of 8 on YMRS is currently recommended by The 
International Society for Bipolar Disorders.
23 The results of 
this study should be interpreted with caution in this respect. 
It is well-known that the combination of various anti-psy-
chotics and mood stabilizers is more effective than a mood 






nation with a mood stabilizer have been shown to cause sig-
nificant weight gain. Obesity has been correlated with a poor 
outcome in patients with bipolar I disorder,
29 and other ad-
verse long-term health consequences. Since weight gain dur-
ing acute treatment may predict a long-term risk for increased 
body weight and obesity,
30 it is important to prevent weight 
gain during the early treatment of bipolar disorder. 
Ziprasidone has been shown to be associated with low risk 
of significant weight gain.
31 Allison et al.
32 analyzed 81 studies 
with respect to weight changes in patients who were treated 
with anti-psychotics. The weight gain recorded included 0.04 
kg for ziprasidone, 2.10 kg for risperidone, 4.15 kg for olan-
zapine, and 4.45 kg for clozapine, which was estimated by the 
random effects regression at 10 weeks of therapy. Another 
comparison study demonstrated that ziprasidone had a more 
benign weight change than other atypical anti-psychotics, ex-
cluding aripiprazole.
33 In this study, the ziprasidone and di-
valproex combination was not associated with weight gain. Be-
cause weight gain is greater with other atypical anti-psychotic 
and mood stabilizer combinations than monotherapy,
24 the 
favorable effect of ziprasidone on weight is an advantage to 
treating with this medication. 
Our study had several limitations. First, because this study 
did not have a placebo control group, the possibility cannot 
be excluded that the improvement could simply be due to 
the natural course of a bipolar disorder. However, the magni-
tude of improvement in the manic symptoms associated with 
the treatment argues against this possibility. Second, the wa-
shout period was too short; 5 half-lives of many anti-psycho-
tics and mood stabilizers are as long as 7 days.
34 Longer wa-
shout periods are needed to rule out the effects of previous me-
dications, especially during the early stage of the study. More-
over, the potential confound of previous medication exposure 
was not addressed. Third, the absence of assessment of other 
clinical variables, such as a history of past year rapid cycling, 
an electrocardiogram (ECG), and other laboratory results, was 
another limitation of our study. Forth, high non-completion 
rate (32.3%), especially in low-dose start group (17/43, 39.5%) 
may have affected the results of this study. Because LOCF do 
not make the unrealistic assumption that subjects who drop 
out would continue improving as they did at the time of drop 
out, the response and remission rates at endpoint in group 
with high non-completion rate could be lower than response 
and remission rates of group with low non-completion rate. 
However, the high non-completion rate observed in low-dose 
start group in this study likely reflects the poor efficacy of 
low-dose start strategy. 
The results of this study should be interpreted with caution 
in light of the limitations, such as the open design. Moreover, 
because Asians may respond to lower doses of anti-psychot-
ics due to pharmacokinetic or pharmacodynamic differenc-
es,
35 the results of this study should be interpreted with some 
reservations. Indeed, potential interethnic differences in 
pharmacodynamics and pharmacokinetics may exist which 
can alter the response to anti-psychotics. Although we con-
ducted careful pre-study education meetings for the investi-
gators, it is possible that observer biases on the rating scales 
in this multi-center study may have influenced the results. 
Finally, we did not include a structured diagnostic interview 
for confirmation of the diagnosis. 
In conclusion, despite the many potential methodologic 
limitations of this open label study, the results of this multi-
center, 6-week investigation showed that ziprasidone in com-
bination with divalproex in the treatment of bipolar disorder 
with acute manic symptoms is safe and effective, especially 
when ziprasidone is initiated at the standard dose. 
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